Effect of Low Molecular Weight Heparin in Freeze-thaw Embryo Transfer Cycles in Women With Recurrent Implantation Failure

The Second Hospital of Shandong University

Status

Completed

Conditions

IVF

Low Molecular Weight Heparin

FET

Recurrent Implantation Failure

Treatments

Drug: Low Molecular Weight Heparine

Study type

Observational

Funder types

Other

Identifiers

NCT06991530

KYLL2025342

Details and patient eligibility

About

Recurrent implantation failure (RIF) is considered a tough problem in assisted reproductive technology (ART) without effective treatments. The effect of low molecular weight heparin (LMWH) in pregnancy outcomes is controversial. In addition, there are few reports on the role of LMWH in population with RIF performing freeze-thaw embryo transfer (FET) cycles. The purpose of this study is to evaluate the effect of LMWH on pregnancy outcomes in women with FET cycles.

Enrollment

392 patients

Sex

Female

Ages

20 to 40 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Women under or equal to the age of 40 when oocytes were retrieved;
The history of at least 2 failed fresh embryo transfer/FET cycles and cumulative transfer of ≥ 3 high-quality embryos or cumulative transfer of ≥ 2 blastocysts;
Planning to FET after IVF or ICSI cycles

Exclusion criteria

Women with untreated hydrosalpinx, uterine cavity occupying lesions (uterine adhesions, submucous fibroids, endometrial polyps, et al.);
Women with abnormal anatomical structure of uterus (unicornuate uterus, bipedal uterus, et al.);
Women with endometrial thickness (EMT) < 6mm on the day of transplantation;
Women or their partner with abnormal chromosome karyotype (not including chromosome polymorphisms);
Women with the history of recurrent spontaneous abortion (RSA);
Women with a history of autoimmune or coagulation disorders;
Women with contraindications to LMWH